For the year ending 2025-12-31, RARE made $673M in revenue. -$575M in net income. Net profit margin of -85.44%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenues | 673 | |||
| Cost of sales | 109 | |||
| Research and development | 750 | |||
| Selling, general and administrative | 349 | |||
| Total operating expenses | 1,208 | |||
| Loss from operations | -535 | |||
| Interest income | 25 | |||
| Non-cash interest expense on liabilities for sales of future royalties | 62 | |||
| Other income (expense) | 1 | |||
| Loss before income taxes | -571 | |||
| (provision for) benefit from income taxes | 4 | |||
| Net loss | -575 | |||
| Net loss per share, basic | -5.83 | |||
| Net loss per share, diluted | -5.83 | |||
| Shares used in computing net loss per share, basic | 98,600,000 | |||
| Shares used in computing net loss per share, diluted | 98,600,000 | |||
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)